JNJ News 102.81 06/19/2014 05:09:09 Johnson & Johnson (JNJ)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Johnson & Johnson (JNJ) 102.81 $JNJ

Final Glance: Pharmaceuticals companies
AP - Wed Jun 18, 5:03PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were up at the close of trading:

Final Glance: Medical Devices companies
AP - Wed Jun 18, 5:03PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were up at the close of trading:

Medtronic vs. Johnson & Johnson: Meet the Market's Biggest New Rivalry
Dan Carroll, The Motley Fool - Motley Fool - Wed Jun 18, 4:10PM CDT
Medtronic 's earth-shaking buy of rival medical device leader Covidien for nearly $43 billion this week didn't just add a new arsenal of products and cash flows to the company's portfolio; the deal also rocked the med-tech landscape. Smaller and...


In odd twist, industry agrees to ban 'microbeads'
By JOHN FLESHER - AP - Wed Jun 18, 3:58PM CDT
TRAVERSE CITY, Mich. (AP) — Environmentalists in Illinois expected a battle royal over their call for a statewide ban on "microbeads" — tiny bits of plastic used in personal care products such as facial scrubs and toothpaste that are flowing by the billions into the Great Lakes and other waterways. Discovered only recently, they're showing up inside fish that are caught for human consumption, scientists say.

Midday Glance: Medical Devices companies
AP - Wed Jun 18, 1:17PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:

Midday Glance: Pharmaceuticals companies
AP - Wed Jun 18, 1:17PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:

Early Glance: Medical Devices companies
AP - Wed Jun 18, 10:36AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:

Early Glance: Pharmaceuticals companies
AP - Wed Jun 18, 10:36AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:

Construction Specialties Receives Sixth Consecutive Champion for Change Award
PRWeb - Wed Jun 18, 9:18AM CDT
Construction Specialties (C/S), a leading manufacturer of high-performing commercial architectural building products such as Acrovyn Wall Protection, Acrovyn Door Systems, Pedisystems Entrance Flooring and C/S Expansion Joint Covers, is pleased to announce that it has been chosen to receive its sixth consecutive Champion for Change Award from Practice Greenhealth. C/S shares this impressive achievement with only one other manufacturer - Johnson & Johnson, makers of health care products and medical devices. The award was presented at CleanMed 2014 in Cleveland, OH, on June 5, 2014, and honors healthcare suppliers that have not only taken steps to improve their organization's green practices but have gone the extra mile to help their clients and associates expand their sustainable practices as well.

ERYTECH adds two new independent members to board
M2 - Wed Jun 18, 5:41AM CDT
ERYTECH Pharma (Paris:ERYP.PA), a French biopharmaceutical company, announced today the appointment of Dr Martine George and Hilde Windels as new independent members to its board of directors.

2014 Report on the International Ophthalmology Diagnostics and Surgical Devices Market - Forecasts to 2019
M2 - Wed Jun 18, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9rfpsb/ophthalmology) has announced the addition of the "2014 Report on the International Ophthalmology Diagnostics and Surgical Devices Market - Forecasts to 2019" report to their offering. Rapid developments in the field of ophthalmology has ensured introduction of efficient diagnosis and treatment methodologies that has rendered enhanced patient outcomes. The ophthalmology market is experiencing an impressive growth globally majorly due to tremendous increase in demand for novel diagnostic technological platforms and efficient treatment methodologies. The ophthalmology sector being an integral part of healthcare sector has witnessed huge growth in terms of scope as well as adoption by patient population owing to rapid technological advances. The speedy growth of the overall medical device industry is considered to be a major driving force for the growth of the ophthalmology diagnostics and surgical devices market. The report analyzes the global market for ophthalmology diagnostics and surgical devices market by three major segments namely, by product type, by applications and by geography. The product type segment has been further categorized into various types of diagnostic and surgical devices along with vision care products. While, the diagnostic devices market has been further classified into fourteen major devices namely, autorefractometers, slit lamps, tonometers, ophthalmoscopes, fundus cameras, fluorescein angiography, optical coherence tomography (OCT) systems, Echography systems, Keratometers, Gonioscopes, Pachymeters, perimeters, corneal topographers and specular microscopes. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global ophthalmology Devices Market, by Product Type Chapter 5 Global Ophthalmology diagnostics and Surgical Devices Market, by Application Chapter 6 Global Ophthalmology Diagnostics and Surgical Devices Market, by Geography Chapter 7 Recommendations Chapter 8 Company Profiles Companies Mentioned: - Abbott Medical Optics, Inc. - Alcon Laboratories, Inc. - Bausch & Lomb, Inc. (Valeant Pharmaceuticals) - Carl Zeiss Meditec AG - CooperVision - Essilor International - Hoya Corporation - Johnson & Johnson - STAAR Surgical Company - SynergEyes, Inc. For more information visit http://www.researchandmarkets.com/research/9r...thalmology

2014 Report on the International Human Reproductive Technologies Market - Forecast to 2019
M2 - Wed Jun 18, 5:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d66cdt/human) has announced the addition of the "2014 Report on the International Human Reproductive Technologies Market - Forecast to 2019" report to their offering. This report covers the market analysis for various drugs, devices and treatment technologies used in assistance and to control human reproduction. The stakeholders for this study include manufacturers and providers of contraceptive technologies and infertility solutions. The market overview section of the report demonstrates the market dynamics and trends such as the drivers, restraints and opportunities that influence the current nature and future status of this field. Impact factors such as market attractiveness analysis and Porter's five forces analysis have also been explained in the market overview section of the report, in order to give a thorough analysis of the overall competitive scenario in the global human reproductive technologies market. The global human reproductive technologies market is categorized on the basis of various infertility treatments and contraceptive technologies. The infertility technologies market is analyzed in this report with respect to drugs as well as types of treatment procedures. With respect to drugs, the report includes leading brands (by sales) from three major classes, namely, gonadotropins, androgens and erectile dysfunction. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Human Reproduction Technologies Market, by Infertility Treatment Chapter 5 Global Human Reproductive Technologies Market, by Contraceptive Technologies Chapter 6 Global Human Reproductive Technologies Market Revenue, by Geography Chapter 7 Recommendations Chapter 8 Company Profiles Companies Mentioned: - Abbott Laboratories, Inc. - Actavis, Inc. - Bayer AG - Church & Dwight, Co. Inc. - Cook Medical, Inc. - Ferring International Center S.A. - Johnson & Johnson - Merck & Co., Inc. - Merck Serono - Pfizer, Inc. - Reckitt Benckiser Group plc - Teva Pharmaceutical Industries Ltd. - Warner Chilcott plc For more information visit http://www.researchandmarkets.com/research/d66cdt/human

J&J's Velcade in Focus at the European Hematology Association - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 17, 4:20PM CDT
Johnson & Johnson (JNJ) presented encouraging data from a phase III study on its oncology drug, Velcade, at the annual meeting of the European Hematology Association.

Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
PR Newswire - Tue Jun 17, 4:00PM CDT
Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, July 15th, to review second-quarter results. Alex Gorsky, Chairman of the Board of Directors and Chief Executive Officer; Dominic Caruso, Vice President, Finance and Chief Financial Officer; Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson and Worldwide Chairman, Pharmaceuticals; Joaquin Duato, Worldwide Chairman, Pharmaceuticals; and Louise Mehrotra, Vice President, Investor Relations, will host the call.

Drugs Drive Growth For Johnson & Johnson
at Investor's Business Daily - Tue Jun 17, 3:58PM CDT
At 128 years old, Johnson & Johnson (JNJ) is still delivering growth and income for its shareholders. It's not Band-Aid bandages and baby oil that's driving growth for the New Brunswick, N.J.-based health-care giant. Out of its three operating units,...

Beck Expands Team With Experienced Director of Operations
PRWeb - Tue Jun 17, 3:04PM CDT
Beck, a print reproduction process authority specialized in enhancing a brand's image on the shelf or any media output, has expanded its executive leadership team with the addition of Jimmy Watkins as Director of Operations. Mr. Watkins brings more than 20 years of design and packaging commercialization expertise, and will be responsible for identifying and implementing process improvements to optimize a brand's color consistency and printed image.

ExxonMobil, Johnson & Johnson Tumble as Dow Gains
Dan Carroll, The Motley Fool - Motley Fool - Tue Jun 17, 1:39PM CDT
The market has struggled to stay on course today, and the Dow Jones Industrial Average  beat back earlier losses to rise 35 points into the green as of 2:35 p.m. EDT. Twelve  of the blue-chip index's 30 member stocks were in the red. ExxonMobil ...

3-D Printing Company Materialise Prices IPO and Is Expected to Begin Trading on June 24
Beth McKenna, The Motley Fool - Motley Fool - Tue Jun 17, 1:03PM CDT
The 3-D printing stocks have taken a bruising in 2014, but that's not stopping Belgium-based Materialise from throwing its hat into the publicly traded ring. IPO terms were released last week, so we can now explore these questions: Does this...
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 78

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 69

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 85

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
ASA’s 2026 Grants Push Dermatology Into New Terrain

Updated Category News Views 104

Thirteen Small Bets With Serious Human Stakes Skin science rarely gets the splashy headlines, yet it touches a staggering number of people and carries some very stubborn unanswered questions. American Skin Association’s 2026 grant class puts 13 awards across skin cancer and dermatologic disease, with a noticeable willingness to follow newer clinical terrain rather than...

Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real

Updated Category News Views 131

GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 169

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 53

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Highmark’s 2026 Rebound Has a Few Asterisks Attached

Updated Category News Views 74

The Headline Needs a Pencil, Not a Highlighter A $1.9 billion net-income figure can look downright thunderous until you separate the cash-generating engine from the accounting cargo strapped to it. Highmark Health reported $26.5 billion in revenue and $741 million in operating income for the nine months ended Sept. 30, 2026. Those are materially better numbers than the...

Continue Reading
Oatly’s $4.13 Tender Offer Is a Legal Detour, Not a Sale

Updated Category News Views 161

A $4.13 cash offer trading against a $7.17 close is the sort of thing that makes investors squint hard, and Verlinvest is practically waving a flag telling them why. This is not a conventional attempt to buy Oatly Group AB. It is a technical tender offer built to satisfy Swedish takeover rules while Verlinvest buys out its joint-venture partner’s interest in Oatly’s...

Continue Reading
Greenberg Traurig Adds Privacy Muscle in Denver Office

Updated Category News Views 162

Privacy work used to be the legal department's back-room plumbing; now it can jam an entire product launch. That is why Greenberg Traurig's decision to bring Amber Mednick in as of counsel in Denver deserves more attention than the usual law-firm hiring blurb. This is not a splashy deal, and nobody should pretend one lateral hire rewrites the competitive map. Still, it is...

Continue Reading

Top 5 Most Recently Viewed Articles

Leech Tishman Expands Healthcare Practice with Nelson Hardiman

Updated Category News Views 79

Leech Tishman Expands Its Healthcare Practice with Major Addition Leech Tishman is making a significant move in its growth strategy by merging with the respected healthcare firm, Nelson Hardiman. This collaboration is set to enhance Leech Tishman’s footprint in the healthcare sector, especially in the Southern California region, as they prepare to operate under the name...

Continue Reading
Schouw & Co. Announces Success in Share Buy-Back Program

Updated Category News Views 105

Schouw & Co. Share Buy-Back Program Overview Schouw & Co., a notable player in the business landscape, has embarked on an impactful share buy-back program that began recently. This strategic move allows the company to purchase shares worth up to DKK 50 million over a designated time frame, from January 2 to March 31. Such initiatives reflect the company's commitment to...

Continue Reading
Earnings Season Set to Shape Market Dynamics Amid Tariffs

Updated Category News Views 150

Understanding Market Sentiment During Earnings Season The upcoming earnings season presents an opportunity for Wall Street to shift its attention from external geopolitical factors to the internal dynamics of corporate performance. As companies prepare to unveil their second-quarter earnings reports, a closer look at how tariffs could influence consumer spending and,...

Continue Reading
Josh Ruben Joins the Board of PetVivo Holdings to Drive Growth

Updated Category News Views 316

Josh Ruben Joins PetVivo Holdings, Inc. Board of Directors PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW) has announced the addition of Josh Ruben to its Board of Directors. This news comes from the company's efforts to further establish itself within the biomedical device sector aimed at improving the quality of life for companion animals. Transformational Leadership...

Continue Reading
Innovative Portable Solar and Wind Generator Concept Unveiled

Updated Category News Views 120

Your Sustainable Charging Solution We live in a time where sustainable energy solutions are becoming more paramount, and the invention of a portable solar and wind-powered generator meets that demand head-on. The concept builds on the idea that everyone deserves access to clean energy alternatives, especially for charging electronic devices. The Vision Behind the...

Continue Reading